As rare disease trials face persistent feasibility challenges, Bayesian designs are gaining momentum by enabling more ...

Ideally, specific treatment for a cancer patient is decided by a multidisciplinary tumor board, integrating prior clinical experience, published data, and patient-specific factors to develop a ...

WASHINGTON, Jan. 20, 2026 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has issued new draft guidance modernizing statistical methodologies used in clinical trials, formally recognizing ...

The FDA has opened the door to the use of Bayesian statistical methods in clinical trials. The worry: Introducing ...

Many antineoplastics are designed to target upregulated genes, but quantifying upregulation in a single patient sample requires an appropriate set of samples for comparison. In cancer, the most ...